SCHEMBL8344571

SCHEMBL8344571

CN(C)c1ccc2cccc(O)c2n1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 2/20 0.58
NCF1 P14598 2/20 0.53
PLAU P00749 1/20 0.53
ALOX12 P18054 2/20 0.52
ALDH1A1 P00352 1/20 0.52
CYP1A2 P05177 1/20 0.52
CYP3A4 P08684 1/20 0.52
CYP2C9 P11712 1/20 0.52
HPGD P15428 1/20 0.52
CYP2C19 P33261 1/20 0.52
HIF1A Q16665 1/20 0.52
HSD17B10 Q99714 1/20 0.52
KDM4E B2RXH2 7/20 0.50
KMT2A Q03164 6/20 0.49
SOS2 Q07890 1/20 0.49
PIM1 P11309 1/20 0.47
TSHR P16473 2/20 0.47
MMP2 P08253 1/20 0.47
CHRM1 P11229 1/20 0.47
COMT P21964 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3230745 0.89 METAP2 (0.58) METAP2NCF1PLAUALOX12ALDH1A1
SCHEMBL15830493 0.78 NCF1 (0.57) METAP2NCF1ALDH1A1CYP1A2CYP3A4
SCHEMBL12827741 0.77 METAP2 (0.46) METAP2NCF1PLAUALOX12ALDH1A1
SCHEMBL5370914 0.77 NCF1 (0.50) METAP2NCF1CYP1A2KDM4EKMT2A
SCHEMBL12747684 0.76 METAP2 (0.45) METAP2NCF1PLAUALOX12ALDH1A1
SCHEMBL359691 0.75 METAP2 (0.47) METAP2NCF1PLAUALOX12ALDH1A1
SCHEMBL19170571 0.74 NCF1 (0.47) NCF1ALDH1A1CYP1A2CYP3A4HPGD
SCHEMBL19287815 0.74 NCF1 (0.47) NCF1ALDH1A1CYP1A2CYP3A4HPGD
SCHEMBL15935191 0.74 NCF1 (0.47) METAP2NCF1ALDH1A1CYP1A2CYP3A4
8-Hydroxy Quinaldine SCHEMBL297247 0.74 METAP2 (1.00) METAP2NCF1PLAUALOX12ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10000511-B2 Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders DANA-FARBER CANCER INSTITUTE, INC. (US) 2018-06-19 US disclosed
US-10000511-B2 Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders DANA-FARBER CANCER INSTITUTE, INC. (US) 2018-06-19 US disclosed
US-20170281649-A1 COMPOUNDS AND THERAPEUTIC USES UNITY BIOTECHNOLOGY, INC. 2017-10-05 US disclosed
US-20170281649-A1 COMPOUNDS AND THERAPEUTIC USES UNITY BIOTECHNOLOGY, INC. 2017-10-05 US disclosed
US-9302993-B2 8-hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2016-04-05 US disclosed
US-9302993-B2 8-hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2016-04-05 US disclosed
US-20150335635-A1 8-HYDROXY QUINOLINE DERIVATIVES PRANA BIOTECHNOLOGY LIMITED (AU) 2015-11-26 US disclosed
US-20150335635-A1 8-HYDROXY QUINOLINE DERIVATIVES PRANA BIOTECHNOLOGY LIMITED (AU) 2015-11-26 US disclosed
US-20150315211-A1 SMALL MOLECULES FOR THE MODULATION OF MCL-1 AND METHODS OF MODULATING CELL DEATH, CELL DIVISION, CELL DIFFERENTIATION AND METHODS OF TREATING DISORDERS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-11-05 US disclosed
US-9169211-B2 8-hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2015-10-27 US disclosed
US-20110071167-A1 METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) PRANA BIOTECHNOLOGY LIMITED (AU) 2011-03-24 US disclosed
US-20110071167-A1 METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) PRANA BIOTECHNOLOGY LIMITED (AU) 2011-03-24 US disclosed
US-20100144693-A1 METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) PRANA BIOTECHNOLOGY LIMITED (AU) 2010-06-10 US disclosed
US-20100144693-A1 METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) PRANA BIOTECHNOLOGY LIMITED (AU) 2010-06-10 US disclosed
US-7619091-B2 Treating nervous system disorders such as mild cognitive impairment, Alzheimer's disease or dementia associated with Down syndrome; e.g. use of 5,7-dichloro-8-hydroxy-2-(2-pyridyl)-quinoline (PBT 1052) PRANA BIOTECHNOLOGY LIMITED (AU) 2009-11-17 US disclosed
US-7619091-B2 Treating nervous system disorders such as mild cognitive impairment, Alzheimer's disease or dementia associated with Down syndrome; e.g. use of 5,7-dichloro-8-hydroxy-2-(2-pyridyl)-quinoline (PBT 1052) PRANA BIOTECHNOLOGY LIMITED (AU) 2009-11-17 US disclosed
US-20080161353-A1 8-Hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2008-07-03 US disclosed
US-20080161353-A1 8-Hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2008-07-03 US disclosed
WO-2007118276-A1 METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION(AMD) PRANA BIOTECHNOLOGY LTD (AU) 2007-10-25 WO disclosed
WO-2004007461-A1 8-HYDROXY QUINOLINE DERIVATIVES PRANA BIOTECHNOLOGY LIMITED (AU) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170281649-A1 COMPOUNDS AND THERAPEUTIC USES TP53, NQO1, SHMT2 METAP2 2146/4885NCF1 673/4885PLAU 2880/4885
US-20150335635-A1 8-HYDROXY QUINOLINE DERIVATIVES PARK7, COQ8A, NLN METAP2 1832/4885NCF1 2693/4885PLAU 2218/4885
US-20080161353-A1 8-Hydroxy quinoline derivatives PARK7, COQ8A, NLN METAP2 1832/4885NCF1 2693/4885PLAU 2218/4885
US-10000511-B2 Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders MCL1, BCL2, BCL2L1 METAP2 3939/4885NCF1 665/4885PLAU 3982/4885
US-20150315211-A1 SMALL MOLECULES FOR THE MODULATION OF MCL-1 AND METHODS OF MODULATING CELL DEATH, CELL DIVISION, CELL DIFFERENTIATION AND METHODS OF TREATING DISORDERS MCL1, BCL2, BCL2L1 METAP2 3939/4885NCF1 665/4885PLAU 3982/4885
US-20100144693-A1 METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) ALDH1A2, AGER, PDE6C METAP2 695/4885NCF1 1011/4885PLAU 444/4885
US-20110071167-A1 METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) ALDH1A2, AGER, PDE6C METAP2 695/4885NCF1 1011/4885PLAU 444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.